y-3 for
Tolerability
Neurodawn Pharmaceutical Co., Ltd.Phase 1Active
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the Tolerability cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Rivoceranib Anhui Provincial Hospital | Phase 3 | B |
Fluzoparib Anhui Provincial Hospital | Phase 3 | B |
Famitinib Anhui Provincial Hospital | Phase 3 | B |
Botanical Extract From Passiflora Incarnata Ativus Farmaceutica Ltda | Phase 3 | B |
Test Product Hy07121 Sichuan Huiyu Pharmaceutical Co., Ltd | Phase 1/2 | CC |
View all 10 →
Same molecule, other indications
y-3 for is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →